• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of gutGutView this articleSubmit a manuscriptReceive email alertsContact usBMJ
Gut. Apr 2001; 48(4): 558–564.
PMCID: PMC1728256

Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders

Abstract

BACKGROUND/AIMS—Hepatocellular carcinoma (HCC) is a common malignant tumour worldwide, and its differential diagnosis from benign lesions of the liver is often difficult yet of great clinical importance. In the present study, we analysed whether glypican-3 is useful in differentiating between benign and malignant liver diseases and whether it influences the growth behaviour of HCC.
METHODS—Northern blot analysis and in situ hybridisation.
RESULTS—Northern blot analysis indicated that expression of glypican-3 mRNA was either low or absent in normal liver, in focal nodular hyperplasia (FNH), and in liver cirrhosis. In contrast, expression of glypican-3 mRNA was markedly increased in 20 of 30 and moderately increased in five of 30 HCC samples. The average increase in glypican-3 mRNA expression in HCC was significant compared with expression in normal liver (21.7-fold increase, p<0.01). In comparison with FNH or liver cirrhosis, glypican-3 mRNA expression in HCC was increased 7.2- (p<0.05) and 10.8-fold (p<0.01), respectively. In addition, pushing HCCs exhibited significantly higher glypican-3 mRNA expression than invading tumours (p<0.05). In situ hybridisation analysis demonstrated weak expression of glypican-3 mRNA in normal hepatocytes and bile ductular cells, and weak to occasionally moderate signals in hepatocytes forming nodules of liver cirrhosis and in regenerated hepatic nodules of FNH. In contrast, glypican-3 in situ hybridisation signals were intense in hepatic cancer cells with even higher levels in pushing HCCs than in invading HCCs.
CONCLUSIONS—These findings suggest that glypican-3, in many cases, has the potential to differentiate between benign and malignant liver diseases.


Keywords: focal nodular hyperplasia; liver cirrhosis; hepatocellular cancer; glypican-3

Full Text

The Full Text of this article is available as a PDF (224K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Haydon GH, Hayes PC. Screening for hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 1996 Sep;8(9):856–860. [PubMed]
  • Pergolizzi JV, Jr, Auster M, Conaway GL, Sardi A. Cryosurgery for unresectable primary hepatocellular carcinoma: a case report and review of literature. Am Surg. 1999 May;65(5):402–405. [PubMed]
  • Hytiroglou P, Theise ND. Differential diagnosis of hepatocellular nodular lesions. Semin Diagn Pathol. 1998 Nov;15(4):285–299. [PubMed]
  • Arnoletti JP, Brodsky J. Surgical treatment of benign hepatic mass lesions. Am Surg. 1999 May;65(5):431–433. [PubMed]
  • Paine-Saunders S, Viviano BL, Saunders S. GPC6, a novel member of the glypican gene family, encodes a product structurally related to GPC4 and is colocalized with GPC5 on human chromosome 13. Genomics. 1999 May 1;57(3):455–458. [PubMed]
  • Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A, Schlessinger D. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 1996 Mar;12(3):241–247. [PubMed]
  • Pellegrini M, Pilia G, Pantano S, Lucchini F, Uda M, Fumi M, Cao A, Schlessinger D, Forabosco A. Gpc3 expression correlates with the phenotype of the Simpson-Golabi-Behmel syndrome. Dev Dyn. 1998 Dec;213(4):431–439. [PubMed]
  • Gonzalez AD, Kaya M, Shi W, Song H, Testa JR, Penn LZ, Filmus J. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol. 1998 Jun 15;141(6):1407–1414. [PMC free article] [PubMed]
  • Lin H, Huber R, Schlessinger D, Morin PJ. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res. 1999 Feb 15;59(4):807–810. [PubMed]
  • Murthy SS, Shen T, De Rienzo A, Lee WC, Ferriola PC, Jhanwar SC, Mossman BT, Filmus J, Testa JR. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene. 2000 Jan 20;19(3):410–416. [PubMed]
  • Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology. 1997 Apr;25(4):862–866. [PubMed]
  • Hisaka T, Yano H, Haramaki M, Utsunomiya I, Kojiro M. Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation. Int J Oncol. 1999 Mar;14(3):453–460. [PubMed]
  • Hamazaki K, Yunoki Y, Tagashira H, Mimura T, Mori M, Orita K. Epidermal growth factor receptor in human hepatocellular carcinoma. Cancer Detect Prev. 1997;21(4):355–360. [PubMed]
  • Roskams T, Moshage H, De Vos R, Guido D, Yap P, Desmet V. Heparan sulfate proteoglycan expression in normal human liver. Hepatology. 1995 Apr;21(4):950–958. [PubMed]
  • Roskams T, Rosenbaum J, De Vos R, David G, Desmet V. Heparan sulfate proteoglycan expression in chronic cholestatic human liver diseases. Hepatology. 1996 Sep;24(3):524–532. [PubMed]
  • Roskams T, De Vos R, David G, Van Damme B, Desmet V. Heparan sulphate proteoglycan expression in human primary liver tumours. J Pathol. 1998 Jul;185(3):290–297. [PubMed]
  • Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997 Nov 15;57(22):5179–5184. [PubMed]
  • Baer HU, Gertsch P, Matthews JB, Schweizer W, Triller J, Zimmermann A, Blumgart LH. Resectability of large focal liver lesions. Br J Surg. 1989 Oct;76(10):1042–1044. [PubMed]
  • Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, Schmid RM, Büchler MW. bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut. 1998 Sep;43(3):414–421. [PMC free article] [PubMed]
  • Kleeff J, Ishiwata T, Kumbasar A, Friess H, Büchler MW, Lander AD, Korc M. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest. 1998 Nov 1;102(9):1662–1673. [PMC free article] [PubMed]
  • Ferrell L. Hepatocellular nodules in the cirrhotic liver: diagnostic features and proposed nomenclature. Pathology (Phila) 1994;3(1):105–117. [PubMed]
  • Bassel K, Lee M, Seymour NE. Focal nodular hyperplasia of the liver. South Med J. 1994 Sep;87(9):918–920. [PubMed]

Figures and Tables

Figure 1
Northern blot analysis of glypican-1, -3, -4, and -6 in normal liver, liver cirrhosis, hepatocellular carcinoma (HCC), and focal nodular hyperplasia (FNH). Total RNA (20 µg) was size fractionated, blotted, and ...
Figure 2
Northern blot analysis. (A) Glypican-3 mRNA in normal liver, focal nodular hyperplasia (FNH), liver cirrhosis, and hepatocellular carcinoma (HCC). (B) Northern blot analysis of glypican-3 mRNA in normal liver and HCC. Total RNA (20 µg) ...
Figure 3
Densitometric analysis. The ratio of the optical density of glypican-3 mRNA to the corresponding 7S signals was calculated and expressed as mean (SEM). FNH, focal nodular hyperplasia; HCC, hepatocellular carcinoma. p<0.01 (HCC v normal); p<0.05 ...
Figure 4
In situ hybridisation of glypican-3 in normal liver tissue (A, B), focal nodular hyperplasia (FNH) (C, D), liver cirrhosis (E, F), and hepatocellular carcinoma (HCC) (G, H). In normal liver tissues, weak glypican-3 mRNA signals were present in bile ductal ...

Articles from Gut are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...